Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2124587 | 1.00 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL22468368 | 1.00 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL20590846 | 0.88 | LMNA (0.33) | ALDH1A1 | |
| SCHEMBL22719629 | 0.88 | LMNA (0.33) | ALDH1A1 | |
| SCHEMBL7345868 | 0.87 | POLB (0.31) | — | |
| SCHEMBL28033257 | 0.82 | — | — | |
| SCHEMBL12469001 | 0.81 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL478853 | 0.81 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL637133 | 0.81 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL1439824 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542253-B2 | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine | Oyster Point Pharma, Inc. (US) | 2023-01-03 | — | — | US | claimed |
| US-9981949-B2 | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine | Oyster Point Pharma, Inc. (US) | 2018-05-29 | — | — | US | claimed |
| EP-2358670-B1 | A process for the preparation of tert-butyl (R)-3-vinylpyrrolidine-1-carboxylate and intermediates therefor | TARGACEPT INC (US) | 2012-10-24 | — | — | EP | claimed |
| EP-2358670-A2 | Novel compounds | Targacept Inc. (US) | 2011-08-24 | — | — | EP | claimed |
| WO-2010065447-A2 | NOVEL COMPOUNDS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | WO | claimed |
| EP-4536653-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | Eisai R&D Management Co., Ltd. (JP) | 2025-04-16 | — | — | EP | disclosed |
| WO-2023239906-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-12-14 | — | — | WO | disclosed |
| EP-4247817-A1 | MACROCYCLES CONTAINING A 1,3,4-OXADIAZOLE RING FOR USE AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230295126-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE | TARGACEPT, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230099745-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2023-03-30 | — | — | US | disclosed |
| US-11542253-B2 | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine | Oyster Point Pharma, Inc. (US) | 2023-01-03 | — | — | US | disclosed |
| WO-2022109573-A1 | MACROCYCLES CONTAINING A 1,3,4-OXADIAZOLE RING FOR USE AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-05-27 | — | — | WO | disclosed |
| EP-2358670-A2 | Novel compounds | Targacept Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010147938-A2 | REVERSAL OF L-DOPA-INDUCED DYSKINESIA BY NEURONAL NICOTINIC RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010141809-A1 | ARYL-SUBSTITUTED HETEROCYCLIC UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010065447-A3 | A PROCESS FOR THE PREPARATION OF TERT-BUTYL (R) - 3 -VINYLPYRROLIDINE- I - CARBOXYLATE AND INTERMEDIATES THEREFOR | TARGACEPT, INC. (US) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010065449-A1 | (R) -3- (E) -2- (PYRR0LIDIN-3-YL) VINYL) -5- (TETRAHYDR0PYRAN-4-YL0XY) PYRIDINE, ITS SALTS, ITS SYNTHESIS AND ITS USE AS LIGAND FOR NICOTINIC ACETYLCHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065443-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-(PYRROLIDIN-3-YLVINYL)PYRIMIDINE | TARGACEPT, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065447-A2 | NOVEL COMPOUNDS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065447-A2 | NOVEL COMPOUNDS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295126-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE | DPYD, DHPS, NUDT5 | ALDH1A1 2295/4885 |
| US-11542253-B2 | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine | DPYD, DHPS, NUDT5 | ALDH1A1 2295/4885 |
| US-20230099745-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | ALDH1A1 3972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.